Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Chengdu Easton Biopharmaceuticals Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥34.21 |
52 Week High | CN¥43.71 |
52 Week Low | CN¥29.53 |
Beta | -0.035 |
11 Month Change | -10.23% |
3 Month Change | -9.73% |
1 Year Change | -8.33% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -32.70% |
Recent News & Updates
Recent updates
Shareholder Returns
688513 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -7.2% | -3.7% | -2.2% |
1Y | -8.3% | -17.3% | -17.9% |
Return vs Industry: 688513 exceeded the CN Pharmaceuticals industry which returned -17.3% over the past year.
Return vs Market: 688513 exceeded the CN Market which returned -17.9% over the past year.
Price Volatility
688513 volatility | |
---|---|
688513 Average Weekly Movement | 4.2% |
Pharmaceuticals Industry Average Movement | 5.6% |
Market Average Movement | 6.7% |
10% most volatile stocks in CN Market | 10.1% |
10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 688513 has not had significant price volatility in the past 3 months.
Volatility Over Time: 688513's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 1,400 | Mingxu Yuan | www.eastonpharma.cn |
Chengdu Easton Biopharmaceuticals Co., Ltd. engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms in anesthetic/analgesics, cardiovascular, oncology, pediatrics, and other therapeutic fields. It also offers active pharmaceutical ingredients in oncology, cardiovascular, anesthetic/analgesics, anti-inflammatory, gastrointestinal, antiemetic, neurology/psychiatry, and urinary system therapeutic categories.
Chengdu Easton Biopharmaceuticals Co., Ltd. Fundamentals Summary
688513 fundamental statistics | |
---|---|
Market cap | CN¥5.98b |
Earnings (TTM) | CN¥240.60m |
Revenue (TTM) | CN¥1.15b |
24.9x
P/E Ratio5.2x
P/S RatioIs 688513 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688513 income statement (TTM) | |
---|---|
Revenue | CN¥1.15b |
Cost of Revenue | CN¥240.17m |
Gross Profit | CN¥914.09m |
Other Expenses | CN¥673.49m |
Earnings | CN¥240.60m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 20, 2024
Earnings per share (EPS) | 1.38 |
Gross Margin | 79.19% |
Net Profit Margin | 20.84% |
Debt/Equity Ratio | 7.6% |
How did 688513 perform over the long term?
See historical performance and comparisonDividends
1.7%
Current Dividend Yield29%
Payout RatioDoes 688513 pay a reliable dividends?
See 688513 dividend history and benchmarksChengdu Easton Biopharmaceuticals dividend dates | |
---|---|
Ex Dividend Date | Jul 01 2024 |
Dividend Pay Date | Jul 01 2024 |
Days until Ex dividend | 0 days |
Days until Dividend pay date | 0 days |
Does 688513 pay a reliable dividends?
See 688513 dividend history and benchmarks